Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Rises By 318.5%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 589,700 shares, a growth of 318.5% from the June 30th total of 140,900 shares. Based on an average daily volume of 4,780,000 shares, the days-to-cover ratio is presently 0.1 days.

Biodexa Pharmaceuticals Trading Down 2.4 %

NASDAQ:BDRX traded down $0.02 on Thursday, reaching $0.76. 89,174 shares of the stock traded hands, compared to its average volume of 3,121,739. The company’s 50 day moving average is $1.00 and its 200-day moving average is $1.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.26 and a current ratio of 1.26. Biodexa Pharmaceuticals has a 1-year low of $0.67 and a 1-year high of $9.64.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.